1. Market Research
Pharma-Patient Engagement: insights from patient opinion leaders

Pharma-Patient Engagement: insights from patient opinion leaders

  • June 2014
  • 71 pages
  • ID: 2171805
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents




TPatients and Pharma want the same thing, but for different reasons. Patients want access, support and information about the latest drugs while Pharma needs market access for sales and profits that will to fund more research. So, they are natural bedfellows....?

Patient pressure and influence across the range of Pharma's activities is growing. While Patient Advocacy Groups are well established, there is a new breed of patient, empowered by the digital revolution, and with access to a wide-range of clinical and health data. These advocates share information and experiences with fellow patients, are informed about their condition, keen to take an informed part in their diagnosis and treatment, and are no longer willing to abdicate decision-making to health professionals.

Collectively, they have political weight, independence and a high social profile: so what do patients want – and expect – from Pharma?

Talking the talk

For its part, Pharma speaks the language of patient-centricity but doesn't always deliver. Bound by regulations in many countries limiting what can, and cannot, be communicated to patients or put in the public domain, industry has struggled to square demands for more openness with regulatory regimes that actively limit its ability to communicate with end-user customers. That could be a generous interpretation: perhaps getting too close to patients presents unacceptable risk to reputation, independence, and the prevailing business model.

Whatever Pharma does, it will meet with concern that when profit is part of the health equation, then its motives can be questioned. The funding of patient groups and related patient focused initiatives leaves Pharma open to the accusation that by encouraging "pester power" and patient pressure on health payers and Health-Technology Assessment bodies, it can achieve what it is unable to do through normal regulatory channels: encourage reimbursement and product uptake while driving sales.

Time to catch up

With the community and voice the internet has given patients, demand for information and dialogue is developing rapidly. The industry's response – whether by choice or regulatory burden – has not. If the common aims of patients and Pharma are to be truly mutually beneficial, the industry has to up its patient–relations game.







Essential insight in this new report: Pharma-Patient Engagement

This closely argued and concise management report from FirstWord combines keen market observations with the insights of leading players in patients groups. It presents a compelling analysis of the issues and examines key drivers such as:

Understanding patient needs and which support services mean most to them
How patient groups and industry can best collaborate to achieve common goals
Understanding which digital communication channels work best, and what pitfalls to avoid
What industry can do to counter the often cynical light it is seen in
How engaging with patient groups can lead to better clinical-research design and outcomes
The need to take a positive, open role in the patient information debate and assess the benefits of getting it right




For senior management, marketing and communication executives, this report is a timely reminder that industry must do more to harness and engage with the rapidly growing power of the patient.

Insights from the report

"Provide the patient groups with independent funding to do what patients really need, instead of doing your own programmes and failing on their compliance, restrictions and barriers. Rather than spending so much money on these kinds of single-sponsor awareness programmes, why doesn't industry set up a fund to support organizations with core funding, removing any suspicion of undue influence?" Jan Geissler, cancer survivor, patient advocate and Director of the European Patients Academy on Therapeutic Innovation (EUPATI)

"I would say from this point onwards, pharma should expect to see much more feedback and much more pressure from patient-driven social media platforms, patient groups, around what they do, how they act, their models, their pricing and so on, and as a result will be forced to become more transparent and to justify things much more than they have been in the past," Eric Low, Chief Executive, Myeloma UK

"We patients want to have the keys to the car. We patients want to be in control of our own destiny with the pharmaceutical industry, with hospitals – with physicians truly being our consultants in an adult-to-adult relationship, not a parent/child relationship." Andrew Schorr, patient advocate and founder of Patient Power LLC

"It's always better to have support from as many companies as possible. Otherwise, the perception is that you're in the pocket of one company." Lizzie Graham, Director of Fundraising and Global Communications, the European Parkinson's Disease Association












Use this report to:

Understand how the patient/Pharma relationship will be critical in the future
Define what patients expect from Pharma
Know how social media is changing the face of patient power and communication
Capitalise on the benefits of working effectively with patient groups for common aims
Communicate key data and information effectively in a controlling regulatory environment

Experts Interviewed
Ilaria Passarani, head of the Food and Health Department, European Consumer Organisation (BEUC)
Andrew Schorr, patient advocate and founder of Patient Power LLC
Lizzie Graham, Director of Fundraising and Global Communications, the European Parkinson's Disease Association (EPDA)
Jan Geissler, patient advocate and Director of the European Patients Academy on Therapeutic Innovation (EUPATI)
Drew Lindon, Head of Policy and Campaigns, Prostate Cancer UK
Eric Low, Chief Executive, Myeloma UK
Michael Seres, patient advocate





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Data Converter Industry

Global Data Converter Industry

  • $ 4950
  • February 2020

Data Converter market worldwide is projected to grow by US$1.8 Billion, driven by a compounded growth of 6%. Analog-to-Digital Converter, one of the segments analyzed and sized in this study, displays ...

2020 Germany Microbiology Analyzers and Reagent for 100 Tests: Supplier Shares and Strategies, Volume and Sales Segment Forecasts by Product--Competitive Profiles, Technology and Instrumentation Review, Opportunities for Suppliers

2020 Germany Microbiology Analyzers and Reagent for 100 Tests: Supplier Shares and Strategies, Volume and Sales Segment Forecasts by Product--Competitive Profiles, Technology and Instrumentation Review, Opportunities for Suppliers

  • $ 3500
  • February 2020

2020 Germany Microbiology Analyzers and Reagent for 100 Tests: Supplier Shares and Strategies, Volume and Sales Segment Forecasts by Product--Competitive Profiles, Technology and Instrumentation Review, ...

2020 Germany Virology and Bacteriology Market for 100 Tests: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

2020 Germany Virology and Bacteriology Market for 100 Tests: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

  • $ 4300
  • February 2020

2020 Germany Virology and Bacteriology Market for 100 Tests: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for SuppliersThis ...

Global VNA & PACS Industry $ 4950 February 2020


ref:plp2014

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on